IQR – interquartile range; MWU - Mann Whitney U test with 5% False Discovery Rate; Biomarkers in bold represent consensus markers also selected by parametric statistics; †values expressed in ng/ml, al

NIAID Data Ecosystem30

Summary of clinical data in patients with NHL and renal involvement

非霍奇金淋巴瘤

脏器功能指标分析

Hb, hemoglobin; WBC, white blood count; BUN, blood urea nitrogen; SCr, serum creatinine; eGFR: estimated Glomerular Filtration Rate NAG, N-acetyl-pD glucosaminidase enzyme, RBP: retinol-binding protei

NIAID Data Ecosystem10

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

非霍奇金淋巴瘤

临床试验

Objective : To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/

DataCite Commons2020-09-02 更新70

Results of adjusted a space-time cluster analyses performed in SpaceStat, based on 15 nearest neighbours, 999 permutations, and by three different time scales.

流行病学时间分析

非霍奇金淋巴瘤

aAdjusted for previous history of autoimmune disease, HIV/AIDS or organ transplantation. bThe total number of statistically significant cases with a Qik p-value of 0.001, which indicates the number of

NIAID Data Ecosystem10

Prevalence of autoimmune conditions among the B-NHL patients.

资源简介：

相关数据集